Recently, Ahmed et al. (2023) [358] studied the antitumor activity of aloin on estrogen receptor-positive (T47D) and triple negative (MDA-MB-231) breast cancer cell lines, in comparison with the standard anthraquinone doxorubicin (Dox). This evidence concerns the gene ESR1 and breast carcinoma.